Eli Lilly and Company

David L Nelson

James E Audia

James Joseph Droste

Gwyn L Murdoch

Marlene L Cohen

Deborah A Evrard

Pawel Fludzinski

Jaswant S Gidda

Kirk Willis Johnson

Beverley Greenwood

Lee A Phebus

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided 3-ethanamine and 3-ethanamine related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds.

Tetrahydro-beta-carbolines

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.

Tetrahydrobetacarboline compounds

This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a 5-HT.sub.2 antagonist.

Method of treating or ameliorating the symptoms of common cold or

The present invention provides 3-ethanamine and 3-ethanamine related compounds which are useful intermediates and have beneficial central nervous system activity.

Indole-ethanamines

Tetrahydro-beta-carboline compounds having useful central nervous system activity are enclosed.

The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.

Naphthylpiperazinyl compounds useful for treating 5HT.sub.2B receptor

The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using a both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.

Method for treating 5-HT.sub.2B receptor related conditions

Method for treating 5HT.sub.2B receptor related conditions

N-unsubstituted ergolines specifically bind to human 5-HT.sub.2 receptors, and are thus useful in treating diseases such as depression, hypertension and migraine.

Method of blocking human 5-hydroxytryptamine-2 receptors

3-Ethanamine and 3-ethanamine related compounds are provided that are useful intermediates and have beneficial central nervous system activity.

Intermediates to tetrahydro-beta-carbolines

The present invention provides tetrahydro-betacarboline compounds having useful central nervous system activity.

Tetrahydro-.beta.-carbolines

The compound 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of certain gastrointestinal disorders.

Growing community of inventors

Carmel, IN, United States of America

David L Nelson